legal research FAQ

Do not use it. The moment you administer Cartalax for personal health purposes, you are conducting an unapproved human clinical trial on yourself—an act that violates 21 CFR 312.2(a), which defines clinical investigation as any experiment involving a test article administered to a human subject. Without an Investigational New Drug (IND) application approved by the FDA, that administration is unlawful. Research peptides exist in legal commerce exclusively because they are not intended for human use. Self-administration transforms your purchase into possession of an unapproved drug, which—while rarely prosecuted for individual users—removes the legal protection that kept your purchase lawful. If you are considering peptide therapy, consult a licensed physician who can prescribe FDA-approved alternatives or enroll you in a legitimate clinical trial.

Verify whether your state classifies peptides under controlled substance statutes or anabolic steroid laws. Cartalax does not meet the chemical structure definition of an anabolic steroid under the Anabolic Steroid Control Act, but enforcement officers may not distinguish between peptide types during inspections. If your state's law criminalizes "possession with intent to distribute" any substance represented as performance-enhancing, document your research intent clearly. A lab notebook, written hypothesis, or even an email to yourself outlining your research plan establishes that your possession is for investigational purposes, not distribution. State prosecutions of individual researchers possessing peptides are exceedingly rare—nearly all enforcement targets commercial sellers—but documentation provides a complete defense if questioned.

Contact the supplier immediately and request documentation proving the product is a research chemical, not a controlled substance or unapproved drug. Customs seizures typically occur because the package lacks proper labeling, the declared value seems inconsistent with the product description, or the destination country's import rules prohibit the compound. In most cases, you will receive a seizure notice explaining the legal basis—if the notice cites drug importation laws, you may need to provide a research authorization letter or institutional affiliation proof to release the package. If the peptide was mislabeled for human use, do not attempt to retrieve it—accepting delivery of a mislabeled drug could expose you to prosecution. Legitimate suppliers like Real Peptides ship with compliant labeling and provide documentation upon request, significantly reducing seizure risk for domestic orders.

Avoid that supplier. Any website marketing Cartalax with therapeutic claims is violating FDA labeling regulations and selling the peptide as an unapproved drug. Purchasing from such a supplier increases your legal risk because the transaction record—credit card statement, shipping label, email confirmations—documents your participation in an illegal drug transaction, not a lawful research chemical purchase. The FDA's warning letters in 2024 and 2025 specifically targeted phrases like "promotes cartilage health," "supports immune function," and "anti-aging benefits" when applied to research peptides. Suppliers who use that language either do not understand regulatory compliance or are deliberately flouting the law—neither scenario suggests product quality or business longevity. Research peptide suppliers who operate legally never make health claims.

Purchase without institutional credentials is not inherently illegal, but any subsequent use for personal therapeutic administration constitutes possession and use of an unapproved drug. The FDA does not actively monitor individual peptide purchases, but enforcement risk increases if adverse events occur or if the supplier is later investigated and customer records are subpoenaed. Researchers operating independently should maintain documentation demonstrating bona fide research intent. Laboratory notebooks, IRB approvals for animal studies, or publications referencing the compound. To establish a defensible use case. Absent that documentation, the ARA-290 legal position becomes indefensible if questioned.

Using ARA-290 in a human clinical trial requires submission of an Investigational New Drug (IND) application to the FDA, which includes preclinical safety data, proposed trial protocols, informed consent documentation, and IRB approval from the institution conducting the trial. The IND process is resource-intensive and typically undertaken by pharmaceutical companies, academic medical centers, or well-funded research institutions. Not individual practitioners. If your trial is approved, ARA-290 legal use is permitted strictly within the scope of the approved protocol, and all adverse events must be reported to the FDA under post-market surveillance requirements. Outside of an approved IND, no clinical use is lawful.

These claims are misleading. A facility may be FDA-registered (meaning it has notified the FDA of its existence and the products it manufactures), but that does not mean the products themselves are FDA-approved. Similarly, GMP certification applies to manufacturing processes, not individual compounds. A supplier can follow GMP standards while producing unapproved investigational drugs. ARA-290 legal status does not change based on supplier certifications; it remains an unapproved drug regardless of manufacturing quality. Researchers should prioritize suppliers who explicitly label products "for research use only" and refuse to provide therapeutic guidance, as this demonstrates regulatory compliance.

Document your research intent with institutional affiliation and approved protocols. Customs and Border Protection, along with FDA inspectors, evaluate shipments based on context clues: purchasing a single 5mg vial of hexarelin alongside bacteriostatic water, insulin syringes, and alcohol swabs signals personal use, not institutional research. Researchers affiliated with universities or private laboratories should provide institutional email verification, purchase orders on letterhead, and IRB-approved study documentation if requested. Individuals without institutional affiliation have no legal basis to purchase investigational peptides under the research-use exemption. Doing so constitutes acquisition of an unapproved new drug for self-administration, which violates federal law.

Yes, but only under an FDA-approved Investigational New Drug (IND) application. Conducting human research with hexarelin requires submitting an IND to the FDA that includes preclinical safety data, proposed clinical protocol, informed consent documents, and IRB approval from the institution overseeing the trial. The IND pathway is how investigational compounds transition from laboratory research to human testing. It is the only legal route for administering hexarelin to human subjects. Trials conducted without IND approval violate 21 CFR Part 312 and expose researchers to criminal liability, institutional sanctions, and loss of federal research funding.

If you are located outside the United States, ARA-290 legal status is governed by your local regulatory authority. Not FDA policy. Researchers in the EU should consult EMA guidelines on investigational medicinal products; those in Canada should reference Health Canada's prescription drug list; those in Australia must comply with TGA scheduling, which classifies most investigational peptides as prescription-only. International shipments of research peptides face customs inspection risk, and packages may be detained or destroyed if the recipient cannot provide research credentials or import authorization. Before ordering, verify that your jurisdiction permits importation of research-grade peptides and that you have the documentation to clear customs if questioned.

End-user liability is low but not zero if the supplier was operating legally at purchase time. FDA enforcement targets suppliers and distributors, not individual purchasers, unless there is evidence of resale, distribution, or fraudulent misrepresentation of intended use. Retain all documentation including Certificates of Analysis, invoices showing research-use labeling, and any correspondence verifying institutional affiliation. If the supplier marketed hexarelin with therapeutic claims and you purchased it for personal use, you have no legal defense. But prosecution of individual peptide buyers remains exceedingly rare. The greater risk is product loss: seized shipments are not returned, and payments are not refunded.

That supplier is operating outside FDA compliance. Providing dosing guidance, administration protocols, or health outcome claims converts a research chemical into an unapproved drug in the agency's view. Purchasing from such suppliers doesn't make you criminally liable, but it increases the risk of receiving mislabeled, contaminated, or misidentified product. Suppliers willing to violate marketing regulations often cut corners on quality control. Legitimate research suppliers never provide human dosing information; if they do, consider it a red flag.

File an Investigational New Drug application with the FDA before administering GHRP-6 acetate to any human participant. Clinical trials require pre-approval even for compounds already studied extensively in animal models. The IND application must include preclinical safety data, proposed clinical protocol, investigator qualifications, and chemistry/manufacturing documentation proving the peptide meets pharmaceutical-grade purity standards. Once the IND is approved and an Institutional Review Board clears the protocol, you can legally administer GHRP-6 acetate to consenting participants within the trial's scope. This is the only legal pathway for human administration outside of an FDA-approved drug. There is no 'research use' exemption for human dosing.

No licensed physician in the United States can legally prescribe Selank Amidate because it is not an FDA-approved drug. Off-label prescribing applies only to drugs that have passed FDA approval for at least one indication. Selank Amidate has zero approved indications. A physician who writes a prescription for Selank Amidate would be prescribing an unapproved new drug, which violates both FDA regulations and state medical board standards. The prescription would be unenforceable, and no licensed pharmacy could legally dispense it.

Purchasing Selank Amidate for personal research falls into a regulatory gray area. The peptide is legal to buy as a research compound, and possession for non-commercial research purposes is not explicitly prohibited. However, using it for self-administration. Even framed as "personal research". Constitutes off-label use of an unapproved drug, which is illegal. The FDA does not prosecute individual peptide users with the same priority it applies to suppliers, but the legal risk exists. Academic or institutional researchers conducting legitimate preclinical studies face no legal barriers; individuals purchasing for self-experimentation operate outside the law.

Purchasing Semax amidate labeled "for research use only" is legal; self-administering it is not. The regulatory distinction is intent and use, not possession. If you buy the peptide, label it for research, and conduct in vitro experiments, you're compliant. If you reconstitute it for self-injection, you're using an unapproved drug, which violates FDA policy even though possession itself isn't criminal. Enforcement rarely targets individual users, but suppliers who knowingly facilitate personal use face warning letters, seizures, and potential prosecution.

Purchase it directly from a licensed research supplier like Real Peptides with no additional authorization required. Cell culture and in vitro studies do not require FDA oversight as long as the peptide is labeled for research use and not administered to humans. Document the purchase as a research reagent in your lab's inventory system and retain certificates of analysis showing purity verification. Some institutions require internal review for biohazard classification, but GHRP-6 acetate is a non-hazardous synthetic peptide with no special storage or handling requirements beyond standard cold chain management at 2–8°C post-reconstitution.

Provide documentation proving research intent: institutional letterhead, a brief protocol description, and confirmation that the compound will not be administered to humans without IND approval. Customs and Border Protection detains shipments when documentation is missing or when labeling suggests human use. If your peptide is properly labeled "not for human consumption" and accompanied by a research use letter, most detentions are released within 7–14 days. If customs believes the product is intended for personal use, they may destroy it and send a seizure notice. You typically have 30 days to contest, but contesting personal-use seizures rarely succeeds.

No FDA approval is required for animal research with GHRP-6 acetate, but you do need Institutional Animal Care and Use Committee approval if your institution requires it. The FDA regulates drugs intended for human use. Animal research falls under USDA and institutional IACUC protocols, not FDA drug approval pathways. Your IACUC application should reference GHRP-6 acetate by its chemical name, specify dosing protocols, and cite peer-reviewed studies supporting its use in the proposed model. Suppliers like Real Peptides provide detailed product specifications and purity certificates that IACUC committees typically require for protocol approval.

Avoid that supplier. Absence of research-use labeling signals either regulatory ignorance or deliberate non-compliance. Peptides sold without clear research designation create legal risk for both the supplier and the purchaser if the transaction is later interpreted as intended for human consumption. The FDA evaluates intent based on totality of circumstances: product labeling, website marketing language, dosing instructions, and purchaser profile. If a supplier sells GHRP-6 acetate in pre-measured 'cycle' doses with reconstitution instructions written for self-administration, that context transforms the product into an unapproved drug regardless of what the label says. Real Peptides includes explicit research-use documentation with every shipment and provides no dosing guidance for human use. That's compliance by design, not accident.